Jette Brandsen Bundgaard
Analyste en capital-investissement chez Lundbeckfonden Ventures
Provenance du réseau au premier degré de Jette Brandsen Bundgaard
Entité | Type d'entité | Industrie | |
---|---|---|---|
Lundbeckfonden Ventures
Lundbeckfonden Ventures Investment ManagersFinance Lundbeckfonden Ventures (Lundbeckfonden Ventures) is a venture capital firm wholly-owned by the Lundbeck Foundation. The firm was established in 2009 and is headquartered in Copenhagen, Denmark.
5
| Operating Division | Investment Managers | 5 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Jette Brandsen Bundgaard via son réseau personnel
Société | Secteur | Personnes liées | Poste principal |
---|---|---|---|
DYSIS Medical Ltd.
DYSIS Medical Ltd. Medical SpecialtiesHealth Technology DySIS Medical Ltd. designs, develops, manufactures, and markets medical imaging systems. Its imaging systems assist clinicians with non-invasive, in-vivo detection of cancerous and pre-cancerous lesions and provides tools to aid medical practitioners in the detection, grading, and documentation of cervical neoplasia. The company was founded by Costas Balas in 2002 and is headquartered in Livingston, the United Kingdom. | Medical Specialties | Director/Board Member Director/Board Member Director/Board Member | |
Varmx BV
Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
University of Copenhagen | College/University | Undergraduate Degree Graduate Degree | |
Sound Bioventures Management ApS | Investment Managers | Founder Private Equity Investor | |
AURA BIOSCIENCES, INC. | Biotechnology | Director/Board Member Director/Board Member | |
Sound Bioventures Management AB
Sound Bioventures Management AB Investment ManagersFinance Sound Bioventures Management AB is a venture capital firm founded in 2021 by Casper Breum, Johan Kordel and Bibhash Mukhopadhyay. The firm is headquartered in Malmo, Sweden. | Investment Managers | Founder Private Equity Investor | |
SPERO THERAPEUTICS, INC. | Biotechnology | Director/Board Member Director/Board Member | |
Symbion A/S
Symbion A/S General GovernmentGovernment Symbion A/S provides office communities, meeting facilities, conference facilities, business development and capital for start-up companies. The company was founded in 1986 and is headquartered in Copenhagen, Denmark. | General Government | Director/Board Member | |
Curzion Pharmaceuticals, Inc.
Curzion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Curzion Pharmaceuticals, Inc. operates as a pharmaceutical firm. The company is headquartered in San Diego, CA. | Pharmaceuticals: Major | Director/Board Member | |
RENEO PHARMACEUTICALS, INC. | Biotechnology | Director/Board Member | |
Athera Biotechnologies AB
Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Major | Director/Board Member | |
Sound Biotech ApS | Chief Executive Officer | ||
SARomics Biostructures AB
SARomics Biostructures AB BiotechnologyHealth Technology SARomics Biostructures AB provides protein three-dimensional structure determination and structure-based drug discovery services. The firm develops premium structural biology services. It offers crystallography services, which include crystallization screen and structure determination, nuclear magnetic resonance spectroscopy services, such as ligand binding assays/fragment screening, structure determination, and verification of the structural integrity of target protein, gene-to-structure services, such as protein cloning, expression, purification, and structure determination, kinase structures and kinobits, which include pre-made complexes of kinases with small-molecule fragments to serve as a starting point in a discovery project, structure-based drug discovery services, such as hit identification, hit optimization, and lead generation, gene-to lead services, including a combination of gene-to-structure and structure-based drug discovery, and structure-activity protein optimization services. The company was founded by Björn Ulrik Walse, Sven Anders Mikael Akke, Derek W. Logan, Salam Al-Karadaghi, and Bo Svensson in 2006 and is headquartered in Lund, Sweden. | Biotechnology | Director/Board Member | |
Amplyx Pharmaceuticals, Inc.
Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | Pharmaceuticals: Major | Director/Board Member | |
ACACIA PHARMA GROUP PLC | Pharmaceuticals: Other | Director/Board Member | |
BONE SUPPORT AB
BONE SUPPORT AB Medical SpecialtiesHealth Technology BONE SUPPORT AB manufactures orthopedic supplies and equipment. Its products include cerament bone void filler, cerament G with gentamicin, cerament V with vancomycin. The company was founded by Lars Ake Alvar Lidgren in 1999 and is headquartered in Lund, Sweden. | Medical Specialties | Director/Board Member | |
Ziarco Pharma Ltd.
Ziarco Pharma Ltd. BiotechnologyHealth Technology Ziarco Pharma Ltd. provides therapeutics targeting inflammatory and allergic diseases. It focuses on chronic inflammatory skin diseases, atopic dermatitis, and Psoriasis. The company was founded by Michael Yeadon, Wai Leung Liu, Lynn Worth Purkins and Arif Kassam Shivji in 2012 and is headquartered in Sandwich, the United Kingdom. | Biotechnology | Director/Board Member | |
BONESUPPORT HOLDING AB | Medical Specialties | Director/Board Member | |
Iconic Therapeutics, Inc.
Iconic Therapeutics, Inc. BiotechnologyHealth Technology Iconic Therapeutics, Inc. engages in the development of novel therapeutics for the treatment of serious eye disorders. Its product ICON-1, is a novel immune-conjugate fusion protein that works with the body’s immune system to address the root causes of inflammation and angiogenesis together, potentially altering the course of causes of blindness. The company was founded by Alan Garen, Kirk Dornbush, and Michael I. Sherman in 2003 and is headquartered in South San Francisco, CA. | Biotechnology | Director/Board Member | |
Industrifonden
Industrifonden Investment ManagersFinance Industrifonden is a Venture Capital firm, a subsidiary of Government of Sweden founded in 1979. The firm is headquartered in Stockholm. | Investment Managers | Consultant / Advisor | |
NOVO NORDISK A/S | Pharmaceuticals: Major | Corporate Officer/Principal | |
Medinvest AB | Private Equity Investor | ||
BIOM'UP | Medical Specialties | Director/Board Member | |
Breye Therapeutics ApS
Breye Therapeutics ApS Pharmaceuticals: MajorHealth Technology Breye Therapeutics ApS is a biopharmaceutical company based in Copenhagen, Denmark. The Danish company develops novel, oral ophthalmology drugs to address the needs of millions of patients suffering from deteriorating vision due to diabetic retinopathy (DR) or age-related macular degeneration (AMD). Breye Therapeutics' lead program with Danegaptide has a clinically de-risked safety profile and potential for a short and well-accepted clinical regulatory pathway. The company aims to provide less burdensome and more effective treatments for DR and AMD patients, which are currently treated with unpopular intravitreal injections directly into the eye. The company was founded in 2019, and the CEO is Ulrik Mouritzen. | Pharmaceuticals: Major | Director/Board Member | |
University of Oxford | College/University | Doctorate Degree | |
Huron Consulting Services U.K. Ltd.
Huron Consulting Services U.K. Ltd. Miscellaneous Commercial ServicesCommercial Services Pope Woodhead & Associates Ltd. provides management consultancy services. The company was founded on November 9, 2006 and is headquartered in Saint Ivens, the United Kingdom. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Lifescience Dynamics Ltd. | Corporate Officer/Principal | ||
Lundbeckfond Invest A/S
Lundbeckfond Invest A/S Investment ManagersFinance Lundbeckfond Invest A/S (Lundbeckfond Invest) is the investment management subsidiary of the Lundbeck Foundation in Denmark. Established in 1999, the firm is based in Copenhagen and manages the Lundbeck Foundation's investments, aiming for long-term, stable returns with moderate risk, such that the Foundation's net capital is not jeopardized and the Foundation is able to meet its commitments in terms of awarding grants and of laying a capital base for its subsidiaries. | Investment Managers | Director/Board Member | |
Sanifit Therapeutics SA
Sanifit Therapeutics SA BiotechnologyHealth Technology Sanifit Therapeutics SA develops pharmaceuticals for calcification disorders. Its pipeline consists of treatments for calcification disorders, such as calciphylaxis and osteoporosis. The company was founded by Felix Grases in 2004 and is headquartered in Palma de Mallorca, Spain. | Biotechnology | Director/Board Member | |
Lundbeck Foundation
Lundbeck Foundation Investment Trusts/Mutual FundsMiscellaneous Lundbeck Foundation maintains and expands the activities of the Lundbeck Group. It provides funding for scientific research. Its support of scientific activities takes place mainly through the financing of concrete scientific projects in the areas of biomedicine and natural sciences. The firm grants a number of stipends and fellowships, and also supports education and procurement activities in biomedical and natural sciences. The company was founded by Grete Lundbeck on March 4, 1954 and is headquartered in Copenhagen, Denmark. | Investment Trusts/Mutual Funds | Director/Board Member | |
Technical University of Denmark | College/University | Graduate Degree | |
ASANTE SOLUTIONS INC | Medical Specialties | Director/Board Member | |
NEXSTIM PLC | Medical Specialties | Director/Board Member | |
Niels Clauson-Kaas A/S
Niels Clauson-Kaas A/S Miscellaneous Commercial ServicesCommercial Services Niels Clauson-Kaas A/S provides research and experimental development services in the fields of natural sciences and engineering. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
River Vision Development Corp.
River Vision Development Corp. BiotechnologyHealth Technology River Vision Development Corp. develops novel protein therapies. The firm provides therapy for the treatment of graves orbitopathy which is a condition in which an autoimmune response is mounted against tissues behind the eye, causing inflammation, tissue proliferation and excess production of extracellular matrix. The company was founded in 2011 and is headquartered in New York, NY. | Biotechnology | Director/Board Member | |
H. LUNDBECK A/S | Pharmaceuticals: Major | Corporate Officer/Principal | |
Flood Vision, Inc. | Director/Board Member | ||
Acacia Pharma Ltd.
Acacia Pharma Ltd. Pharmaceuticals: MajorHealth Technology Acacia Pharma Ltd. develops supportive care product opportunities for post-surgical and cancer patients. It specializes in the discovery and development of cancer supportive care product opportunities based on established drugs. The firm’s product pipeline addresses supportive care indications, such as post-operative and chemotherapy-induced nausea and vomiting, xerostomia and cachexia. The company was founded by Andrew Muncey, Julian Clive Gilbert and Robert William Gristwood in 2006 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Enterome SA
Enterome SA Pharmaceuticals: MajorHealth Technology Enterome SA develops personalized medical-tests and diagnostics. The firm profiles human gut microbiome to improve management of microbiome-related disease. It primarily specializes in research adn development focusing on disease management. The company was founded by Stanislav Dusko Ehrlich in 2012 and is headquartered in Paris, France. | Pharmaceuticals: Major | Director/Board Member | |
Statens Serum Institute | College/University | Director/Board Member | |
Henley Business School Ltd. | College/University | Masters Business Admin | |
Thesan Pharmaceuticals, Inc.
Thesan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Thesan Pharmaceuticals, Inc. provides novel therapeutics for disorders of the skin. The company focuses on the discovery and development of new chemical entities that provide improved treatment options to patients. Thesan Pharmaceuticals was founded in 2011 by Edward P. Monaghan and is headquartered in Carlsbad, CA. | Pharmaceuticals: Major | Director/Board Member | |
Akamis Bio Ltd.
Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | Biotechnology | Director/Board Member | |
AlloCure, Inc.
AlloCure, Inc. BiotechnologyHealth Technology AlloCure, Inc. develops cell therapies for the treatment of kidney diseases. It engages in developing allogeneic mesenchymal stem cell therapy for acute kidney injury. The company was founded in 2008 and is headquartered in Burlington, MA. | Biotechnology | Director/Board Member | |
DBV TECHNOLOGIES | Pharmaceuticals: Major | Director/Board Member | |
HARBOES BRYGGERI A/S | Beverages: Alcoholic | Director/Board Member |
Statistiques
Internationale
Danemark | 15 |
Etats-Unis | 13 |
Royaume-Uni | 11 |
Suède | 8 |
France | 4 |
Sectorielle
Health Technology | 32 |
Consumer Services | 6 |
Finance | 5 |
Commercial Services | 3 |
Government | 2 |
Opérationnelle
Director/Board Member | 65 |
Private Equity Investor | 11 |
Corporate Officer/Principal | 11 |
Independent Dir/Board Member | 9 |
Founder | 6 |
Relations les plus connectées
Insiders | |
---|---|
Carl Johan Kördel | 31 |
Mette Agger | 30 |
Casper Breum | 18 |
Thomas Tan | 9 |
Johan Kördel | 8 |
- Bourse
- Insiders
- Jette Brandsen Bundgaard
- Connexions Sociétés